IV Methocarbamol After Spine Surgery
Intravenous methocarbamol is a common component of multimodal analgesia protocols for spine surgery. The pharmacologic rationale is straightforward: relieve postoperative muscle spasm, reduce pain, spare opioids. But how strong is the evidence behind this practice? A new study used one of the most rigorous observational designs available to find out, and the results suggest that IV methocarbamol did not meaningfully reduce pain or opioid consumption after elective spine surgery.
This post walks through the key findings, explains why the study methodology is well suited to this clinical question, and highlights what it means for clinicians and trainees working in perioperative pain management.
The Bottom Line
IV methocarbamol administered in the first 2 hours after elective spine surgery did not reduce pain scores or opioid consumption over the subsequent 6 hours compared to usual care, across all analyses.
The study included 1,270 matched patients (635 per group) from a large academic medical center in Houston. After rigorous matching on clinical trajectory, the groups were essentially identical at the moment of the treatment decision: same pain levels, same opioid exposure, same baseline risk. The difference in outcomes? Negligible.
Primary & Secondary Outcomes
Adjusted mean differences with 95% confidence intervals. MCID thresholds shown in red.
Across five separate analyses, including a marginal structural model, exact temporal matching, alternative pain covariate specification, and a dose-restricted subgroup, the conclusion was consistent: no clinically meaningful analgesic benefit. The one sensitivity analysis that reached statistical significance (the marginal structural model, mean difference 0.5, 95% CI 0.3 to 0.7) actually showed pain scores were higher in the methocarbamol group, though the magnitude was well below the prespecified MCID of 1 point.
Sensitivity Analyses at a Glance
Consistency of findings across all analytic approaches for the primary outcome (TWA pain score)
| Analysis | Mean Diff (95% CI) | Result |
|---|---|---|
| Primary (TV-PSM + GEE) | 0.1 (−0.1 to 0.4) | Not significant |
| Marginal structural model | 0.5 (0.3 to 0.7) | Sig, < MCID |
| Exact interval matching | 0.1 (−0.1 to 0.4) | Not significant |
| Prior-interval pain covariate | 0.1 (−0.1 to 0.3) | Not significant |
| 1,000 mg dose only | 0.2 (−0.1 to 0.5) | Not significant |
Why Old Evidence Was Unreliable
Prior studies on muscle relaxants after spine surgery produced contradictory findings. An RCT of tizanidine showed benefit; a trial of chlorzoxazone showed nothing. Two retrospective studies by Komatsu and Perez paradoxically linked muscle relaxants to increased pain and opioid use, but these results were likely driven by confounding by indication: patients who received muscle relaxants were probably in more pain to begin with, and neither study adjusted for treatment timing or accounted for time-dependent confounding.
This is the core challenge with observational studies of as-needed analgesics. A simple before-and-after comparison will always be biased when the treatment decision is driven by the very outcome you are trying to measure. To untangle cause from correlation here, you need a method that respects the time-varying nature of the clinical decision.
The fundamental challenge: clinicians prescribe methocarbamol because a patient is in pain. Comparing those patients to untreated patients will always make the drug look harmful unless you match at the exact moment the decision is made.
Target Trial Emulation: Think Trial First, Then Emulate
Target trial emulation is a framework for causal inference from observational data that starts with a deceptively simple idea: before touching any data, design the randomized trial you wish you could run. Specify the eligibility criteria, treatment strategies, randomization scheme, outcomes, and follow-up. Then, using the observational data you actually have, emulate each component of that hypothetical trial as faithfully as possible.
This approach, formalized by Miguel Hernán and colleagues, encourages researchers to confront possible sources of bias at the design stage rather than treating analysis as an afterthought. It also makes observational studies more directly comparable to RCTs, because the research question is framed in the same language.
Target Trial Emulation Framework
Design the ideal trial, then map each component onto the observational data
For this study, the target trial emulation approach was especially well suited for three reasons. First, it naturally handles the time-dependent treatment decision: methocarbamol is not given at a fixed point but at a clinician-chosen moment based on evolving pain. Second, it explicitly helps prevent starting time bias, where treated and control groups are compared from different points in their recovery. Third, by estimating a per-protocol effect, the analysis addresses what happens when the drug is actually given versus not given, which is the most clinically relevant question.
Time-Varying Propensity Score Matching: Making Apples-to-Apples Comparisons
Standard propensity score matching adjusts for differences at a single baseline time point. But in the PACU, the decision to give methocarbamol is not made at baseline. It is made in real time, as the clinician observes the patient’s pain evolve. A patient who is comfortable at 15 minutes but in significant pain at 45 minutes is a fundamentally different treatment candidate at each time point.
Time-varying propensity score matching (TV-PSM) addresses this by re-estimating the probability of treatment at every 15-minute interval in the PACU, incorporating both fixed baseline characteristics and continuously updating clinical data: pain scores and opioid doses as they accumulate.
How it works
Divide postoperative time into intervals
The first 2 hours after surgery are split into 15-minute intervals, matching standard PACU nursing assessment timing. At each interval, every still-untreated patient is “at risk” of receiving methocarbamol.
Estimate interval-specific propensity scores
A Cox proportional hazards model estimates each patient’s probability of receiving methocarbamol at that interval, conditional on fixed covariates (demographics, comorbidities, surgical factors, intraoperative medications) plus time-varying covariates (cumulative time-weighted average pain score and cumulative opioid use up to that moment).
Match at the moment of treatment
When a patient receives methocarbamol at interval k, the algorithm finds a control patient (still untreated) with the most similar propensity score at any eligible interval. Optimal 1:1 matching minimizes the total propensity score distance across all pairs.
Align “Time Zero” and follow forward
Each matched pair begins 6-hour outcome follow-up from their shared Time Zero, the interval where the treatment decision (or matched equivalent) occurred. This eliminates starting-time bias.
Estimate outcomes in matched pairs
GEE models estimate mean differences within matched pairs, with additional regression adjustment for any residual covariate imbalance (here, cumulative opioid use prior to treatment assignment).
Conceptual Illustration: Matching at the Moment of Decision
How TV-PSM creates fair comparisons by aligning patients at the exact clinical moment
Why this matters clinically
Consider the alternative: a traditional retrospective study comparing “patients who got methocarbamol” versus “patients who didn’t.” The methocarbamol group would have higher pain at baseline (that is why they received the drug), and any analysis would need to overcome substantial confounding. Prior retrospective studies that failed to account for this found paradoxical results, with muscle relaxants apparently increasing pain, almost certainly because of this exact bias.
TV-PSM addresses this by creating a comparison group that was equally likely to receive methocarbamol at that exact moment in their recovery. After matching, the two groups had virtually identical baseline characteristics (all standardized mean differences ≤ 0.1 except one, which was included as an adjustment covariate). The result is the closest approximation to an RCT that can be achieved without actually randomizing, and the findings were consistent across all analytic approaches.
What This Means for Practice
Routine IV methocarbamol in postoperative spine surgery multimodal analgesia protocols is not supported by this evidence. Every unnecessary medication carries costs, potential side effects, and contributes to polypharmacy, which is especially concerning in the older adults who make up much of the spine surgery population.
This is particularly relevant when you consider that muscle relaxants are flagged on the American Geriatrics Society Beers Criteria as potentially inappropriate medications for older adults due to sedation and fall risk. Other research has linked postoperative muscle relaxant use to a two-fold increased risk of delirium after spine surgery. Combining a lack of demonstrated efficacy with real safety concerns, the risk-benefit equation becomes difficult to justify for routine use.
That said, the authors appropriately note that these findings do not rule out a role for methocarbamol in selected patients with clinically evident paraspinal muscle spasm. The study evaluated routine use in a broad surgical population; targeted use in a spasm-specific subgroup remains an open question.
Lessons for Trainees and Researchers
Beyond its clinical conclusions, this paper is worth studying as an example of rigorous observational research design in perioperative medicine. A few highlights:
Preregistration matters. The study was registered on ClinicalTrials.gov before data extraction, with prespecified sensitivity analyses and MCIDs. This helps address concerns about post-hoc hypothesis testing or selective reporting.
Sensitivity analyses build credibility. Five different analytic approaches all converging on a similar result is far more persuasive than any single analysis. When a marginal structural model, exact temporal matching, and alternative covariate specifications all point in the same direction, we can be more confident the finding is robust to analytic choices.
Clinically meaningful thresholds matter. By prespecifying a 1-point MCID for pain and 10 mg OME for opioid use, the authors ensure that statistical significance does not masquerade as clinical importance. This lesson is underscored by the marginal structural model sensitivity analysis, which was statistically significant but clinically irrelevant.
The best observational studies do not just adjust for confounding. They think like trialists, design like trialists, and report with the same rigor.
